William Blair & Company’s Recursion Pharmaceuticals RXRX Stock Holding History

William Blair & Company’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$74K	Sell	20,169 -9,892	-33%	-$32.9K	﹤0.01%	1721
2026 Q1	$92.3K	Sell	30,061 -43,939	-59%	-$170K	﹤0.01%	1605
2025 Q4	$303K	Sell	74,000 -3,033	-4%	-$15K	﹤0.01%	1307
2025 Q3	$376K	Buy	77,033 +33	+0%	+$173	﹤0.01%	1216
2025 Q2	$390K	Sell	77,000 -37,500	-33%	-$184K	﹤0.01%	1163
2025 Q1	$606K	Buy	114,500 +102,500	+854%	+$747K	﹤0.01%	1033
2024 Q4	$81.1K	Buy	+12,000	New	+$80.7K	﹤0.01%	1551

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

William Blair & Company's RXRX Position: Q2 2026 in Review

William Blair & Company reduced its Recursion Pharmaceuticals (RXRX) stake by 33% in Q2 2026, selling an estimated $32.9K and leaving 20,169 shares worth $74K. The position accounts for ﹤0.01% of the portfolio, ranked #1721.

William Blair & Company first reported a position in RXRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $606K in Q1 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

William Blair & Company held 20,169 shares of Recursion Pharmaceuticals worth $74K as of Q2 2026.
William Blair & Company sold 9,892 Recursion Pharmaceuticals shares in Q2 2026, an estimated $32.9K.
Recursion Pharmaceuticals made up ﹤0.01% of William Blair & Company's portfolio in Q2 2026, its #1721 holding.
William Blair & Company first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
William Blair & Company's Recursion Pharmaceuticals position peaked at $606K in Q1 2025.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.